It is in Phase III clinical trials for the treatment of anemia caused by chronic kidney disease.

[2][3] Due to its potential applications in athletic doping, it has also been incorporated into screens for performance-enhancing drugs.

[4] Molidustat is indicated for the control of nonregenerative anemia associated with chronic kidney disease in cats.

[5] The reasonable expectation of effectiveness of Molidustat was evaluated in a study conducted in two phases.

[5] The first phase involved a multi-center, double-masked, randomized, placebo-controlled field effectiveness and safety study.